MDxHealth (MDXH)
NASDAQ:MDXH
Want to see MDXH full AI Analyst Report?
MDXH Stock Chart & Stats
$2.31
-$0.10(-4.55%)
At close: 4:00 PM EST
$2.31
-$0.10(-4.55%)
Day’s Range― - ―
52-Week Range$1.67 - $5.33
Previous CloseN/A
Volume27.23K
Average Volume (3M)194.90K
Market Cap
$111.46M
Enterprise Value$172.92M
Total Cash (Recent Filing)$29.03M
Total Debt (Recent Filing)$95.11M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
May 14, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding51,364,520
10 Day Avg. Volume253,010
30 Day Avg. Volume194,899
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)-14.77
Price to Sales (P/S)1.66
P/FCF Ratio-15.43
Enterprise Value/Market Cap1.55
Enterprise Value/Revenue1.60
Enterprise Value/Gross Profit2.68
Enterprise Value/Ebitda-27.92
Forecast
1Y Price Target
$7.67Price Target Upside231.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.39
Revenue Forecast (FY)$138.30M
Bulls Say, Bears Say
Bulls Say
Clinical Study CatalystsFavorable outcomes from the GPS‑ProMPT study and collaboration to test GPS in the ProtecT trial could strengthen guideline support for active surveillance and increase clinical adoption of the GPS test.
Commercial Refocus And Product MixA redeployed sales force concentrating on higher‑return diagnostics and an appropriate test menu can accelerate commercial traction and raise revenue per customer.
Financial Structure And Cost DisciplineAmended earnout terms together with operating expense discipline improve near‑term liquidity and support progress toward sustainable profitability and positive free cash flow.
Bears Say
Acquisition‑related Expense PressureHigher headcount and acquisition‑related expenses reduced adjusted EBITDA versus expectations, highlighting margin pressure while integration completes.
Integration And Timing DisruptionTiming and integration challenges related to recent acquisitions produced a revenue shortfall, signaling execution risks that could pressure near‑term growth expectations.
Product Prioritization RiskDeprioritizing select legacy products led to a sales shortfall, exposing the risk that strategic shifts in the product mix may temporarily undermine top‑line growth.
MDxHealth News
MDXH FAQ
What was MDxHealth’s price range in the past 12 months?
MDxHealth lowest stock price was $1.67 and its highest was $5.33 in the past 12 months.
What is MDxHealth’s market cap?
MDxHealth’s market cap is $111.46M.
When is MDxHealth’s upcoming earnings report date?
MDxHealth’s upcoming earnings report date is May 14, 2026 which is in 18 days.
How were MDxHealth’s earnings last quarter?
MDxHealth released its earnings results on Feb 26, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.125 by -$0.045.
Is MDxHealth overvalued?
According to Wall Street analysts MDxHealth’s price is currently Undervalued.
Does MDxHealth pay dividends?
MDxHealth does not currently pay dividends.
What is MDxHealth’s EPS estimate?
MDxHealth’s EPS estimate is -0.15.
How many shares outstanding does MDxHealth have?
MDxHealth has 51,364,520 shares outstanding.
What happened to MDxHealth’s price movement after its last earnings report?
MDxHealth reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.125. Following the earnings report the stock price went down -4.225%.
Which hedge fund is a major shareholder of MDxHealth?
Currently, no hedge funds are holding shares in MDXH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MDxHealth Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (231.89% Upside)
$7.67 (231.89% Upside)
Blogger Sentiment
Bullish
MDXH Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 12.9%
Last 30 Days ▲ 12.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
44.37%
12-Months-Change
Fundamentals
Return on Equity
516.59%
Trailing 12-Months
Asset Growth
-5.96%
Trailing 12-Months
Company Description
MDxHealth
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
MDXH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed a company in growth and transition: strong top-line and unit growth (notably a 62% unit increase and 128% rise in liquid volumes), successful integration steps with ExoDx and a clearer path to cross-selling and clinical validation, offset by near-term profitability pressure from integration costs, higher operating and financial expenses, and a modest downward adjustment to reported revenue. Management provided optimistic 2026 guidance (approx. 28% revenue growth and a target of 10% adjusted EBITDA exiting the year) and secured earnout amendment relief (~$20M), signaling confidence in returning to operating leverage despite short-term headwinds.View all MDXH earnings summariesMDXH Stock 12 Month Forecast
Average Price Target
$7.67
▲(231.89% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.26% Mutual Funds
44.29% Other Institutional Investors
54.24% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---